En­her­tu picks up an­oth­er win for As­traZeneca and Dai­ichi Sankyo, join­ing the pri­or­i­ty re­view lane for gas­tric can­cer

Five months af­ter En­her­tu re­ceived twin break­through ther­a­py des­ig­na­tions, As­traZeneca and Dai­ichi Sankyo are one step clos­er to nab­bing an­oth­er ap­proval for their po­ten­tial block­buster drug.

The com­pa­nies an­nounced Wednes­day morn­ing that their bil­lion-dol­lar an­ti­body-drug con­ju­gate has re­ceived pri­or­i­ty re­view for HER2 pos­i­tive metasta­t­ic gas­tric can­cer. Al­ready ap­proved in the US for third-line metasta­t­ic breast can­cer pa­tients that are HER2 pos­i­tive, En­her­tu’s gas­tric can­cer PDU­FA date is sched­uled for the first quar­ter of 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER